These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19701155)

  • 1. Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy.
    Chalasani P; Shtivelband MI; Cranmer LD
    Clin Adv Hematol Oncol; 2009 Jul; 7(7):473-5. PubMed ID: 19701155
    [No Abstract]   [Full Text] [Related]  

  • 2. Current perspective - trastuzumab.
    Hall PS; Cameron DA
    Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual problems in breast cancer and a rare lung cancer case. Case 1. Clinical complete response of breast cancer metastases after trastuzumab-based immunotherapy.
    Tonini G; Vincenzi B; Santini D; Avvisati G; La Cesa A; Baldi A
    J Clin Oncol; 2003 Jun; 21(11):2215-6. PubMed ID: 12775749
    [No Abstract]   [Full Text] [Related]  

  • 4. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 5. [Medical, non-endocrine treatment of metastatic breast cancer--a status].
    Lindberg H; Nielsen DL; Kamby C
    Ugeskr Laeger; 2007 Apr; 169(17):1556-60. PubMed ID: 17484824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: desmoplastic small round cell tumor: current treatment approach and role of targeted therapy.
    Sankhala KK; Chawla SP
    Clin Adv Hematol Oncol; 2009 Jul; 7(7):476-8. PubMed ID: 19701156
    [No Abstract]   [Full Text] [Related]  

  • 8. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
    Liao C; Yin F; Huang P; Cao Y; Gao F
    Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer].
    Kitagawa D; Toi M
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():396-401. PubMed ID: 17682183
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010).
    Santin AD
    Gynecol Oncol; 2010 Jul; 118(1):95-6; author reply 96-7. PubMed ID: 20172595
    [No Abstract]   [Full Text] [Related]  

  • 11. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.
    Horton JK; Halle J; Ferraro M; Carey L; Moore DT; Ollila D; Sartor CI
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):998-1004. PubMed ID: 19560883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab in the treatment of breast cancer.
    Hortobagyi GN
    N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
    [No Abstract]   [Full Text] [Related]  

  • 13. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
    Burstein HJ; Winer EP
    J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
    [No Abstract]   [Full Text] [Related]  

  • 15. Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports.
    Vandenput I; Vanden Bempt I; Leunen K; Neven P; Berteloot P; Moerman P; Vergote I; Amant F
    Gynecol Obstet Invest; 2009; 67(1):46-8. PubMed ID: 18843183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
    Buzdar AU; Ibrahim NK; Francis D; Booser DJ; Thomas ES; Theriault RL; Pusztai L; Green MC; Arun BK; Giordano SH; Cristofanilli M; Frye DK; Smith TL; Hunt KK; Singletary SE; Sahin AA; Ewer MS; Buchholz TA; Berry D; Hortobagyi GN
    J Clin Oncol; 2005 Jun; 23(16):3676-85. PubMed ID: 15738535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking breast cancer relapses.
    Johns Hopkins Med Lett Health After 50; 2006 Feb; 17(12):1-2. PubMed ID: 17115471
    [No Abstract]   [Full Text] [Related]  

  • 19. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role?
    Kalemkerian G
    J Clin Oncol; 2005 Feb; 23(6):1325-6; author reply 1326-7. PubMed ID: 15718337
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients.
    Salzberg M; Borner M; Bauer JA; Morant R; Rauch D; Rochlitz C
    Eur J Cancer; 2006 Oct; 42(15):2660-1. PubMed ID: 16934972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.